PB 25 of 2014
National Health (Pharmaceutical Benefits – Early Supply) Amendment Instrument 2014 (No. 1) – specification under subsection 84AAA(2)
 
National Health Act 1953
 
I, FELICITY McNEILL, First Assistant Secretary, Pharmaceutical Benefits Division, Department of Health, delegate of the Minister for Health, make this Instrument under subsection 84AAA(2) of the National Health Act 1953.
Dated 21 March 2014
 
 
 
 
 
 
 
 
 
 
 
FELICITY McNEILL
First Assistant Secretary
Pharmaceutical Benefits Division
Department of Health
 
 
 
___________________________________________________________________________
 
 
Amendment determination – Pharmaceutical Benefits – Early Supply
 
 
1          Name of Instrument
 
(1)           This Instrument is the National Health (Pharmaceutical Benefits – Early Supply) Amendment Instrument 2014 (No.1) – specification under subsection 84AAA(2).
 
(2)           This Instrument may also be cited as PB 25 of 2014.
 
 
2          Commencement
 
This Instrument commences on 1 April 2014.
 
3          Amendment of PB 30 of 2009
 
Schedule 1 amends the National Health (Pharmaceutical Benefits – Early Supply) Instrument 2009 – specification under subsection 84AAA(2) (PB 30 of 2009).
 
Schedule 1        Amendments
 
[1]       Schedule 1, entry for Denosumab
substitute:
            
Denosumab
Injection 120 mg in 1.7 mL
Injection
1
5
Bone metastases
The condition must be due to castration-resistant prostate cancer
Bone metastases
The condition must be due to breast cancer
[2]       Schedule 1, entry for Flutamide
omit:
 
 
Tablet 250mg, 30
Oral
3
5
 
[3]       Schedule 1, after entry for Glyceryl trinitrate in the form Transdermal patch 120 mg
insert:
 
Glycopyrronium
Capsule containing powder for oral inhalation 50 micrograms (as bromide) (for use in Breezhaler)
Inhalation by mouth
30
5